DAFTAR PUSTAKA

Abdelhaleem, E.F., Abdelhameid, M.K., Kassab, A.E., Kandeel, M.M., 2017. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. *European Journal of Medicinal Chemistry*, 2017, pp. 1-66.

Aertgeerts, K., Skene, R., Yano, J., Sang, B.C., Zou, H., Snell, G., Jennings, A., Iwamoto, K., Habuka, N., Hirokawa, A., Ishikawa, T., Tanaka, T., Miki, H., Ohta, Y., Sogabe, S., 2011. Structural Analysis of The Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein. *The Journal of Biological Chemistry*, 286(21),pp. 18756-18765.

Aggarwal, V., Tuli, H.S., Varol, A., Thakral, F., Yarer, M.B., Sak, K., Varol, M., Jain, A., Khan, M.A., Sethi, G., 2019. Role of reactive oxygen species in cancer progression: Molecular mechanism and recent advancements. *Biomolecules*, 9(735), pp.1-26.

Airley, R., 2009. *Cancer chemotherapy, Basic Science to the Clinic*. Oxford: John Wiley and Sons Ltd, pp. 67 – 111.

Alanazi, I.O., and Khan, Z., 2016. Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications. *Asian Pacific Journal of Cancer Prevention*, 17(2), pp. 445-453

Al-Hajj, M., 2003. Prospective identification of tumorigenic breast cancer cells. *Proceeding of the National Academy of Science of the United States of America (PNAS)*, 100, pp. 3983-3988.

American Cancer Society, 2011. Breast cancer: What you need to know-Now.

Asati, V., Mahapatra, D. K. and Bharti, S. K., 2017. K-Ras and its inhibitors towards personalized cancer treatment : Pharmacological and structural perspectives. *European Journal of Medicinal Chemistry*, 125 (2017), pp. 299–314.

Badisa, R.B., Darling-Reed, S.F., Joseph, P., Cooperwood, J.S., Latinwo, L.M., Goodman, C.B., 2009. Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. *Anticancer Research*, 29(8), pp. 2993-2996.

Banerjee, K., and Resat, J., 2016. Constitutive activation of STAT3 in breast cancer cells: A review. *International Journal of Cancer*, 138, pp. 2570-2578.

Barbosa, F.A.R., Siminski, T., Canto, R.F.S., Almeida, G.M., Mota, N.S.R.S., Ourique, F., Pedrosa, R.C., Braga, A.L., 2018. Novel pyrimidinic selenourea induces DNA damage, cell cycle arrest, and apoptosis in human breast carcinoma. *European Journal of Medicinal Chemistry*, 2018, pp. 1-55.

Barosi, G., Besses, C., Birgegard, G., Briere, J., Cervantes., F., Finazzi, G., Gisslinger, H., Grisshammer, M., Gugliotta, L., Harrison, C., Hasselbalch, H., Lengfelder, E., Reilly, J.T., Michiels, J.J., and Barbui, T., 2009. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a concensus process by an international working group. *Bioorganic & Medicinal Chemistry Letters*, 19, pp. 755-758.

Basakran, N.S., 2015. CD44 as a potential diagnostic tumor marker. *Saudi Medical Journal*, 36(3), pp. 273-279.

Biolegend, 2020. FITC Annexin V Apoptosis Detection Kit wit PI. Versi 3. Available online: https://www.biolegend.com/en-gb/global-elements/pdf-popup/fitc-annexin-v-apoptosis-detection-kit-with-pi-8230?filename=FITC%20Annexin%20V%20Apoptosis%20Detection%20Kit%20with%20PI.pdf&pdfgen=true (diakses: 18 Juni 2020).

Bhattacharya, S., 2015. Reactive Oxygen Species and Cellular Defense System, In: V. Rani and U.C.S. Yadav, eds. *Free Radicals in Human Health and Disease*. India: Springer India, pp. 17-29.

Birben, E., Sahiner, U.M., Sackesen, C., Erzurum, S., and Kalayci, O., 2012. Oxidative Stress and Antioxidant Defense. WAO *Journal*, 5, pp. 9-19.

Brand, T.M., Lida, M., Li, C., Wheeler, D.L., 2011. The nuclear epidermal growth factor receptor signaling network and its role in cancer. *Discovery Medicine*, 12(66), pp. 419-432.

Bruice, P. Y., 2014. *Organic Chemistry*, 7th Ed, Prentice Hall, Upper Saddle River, NJ, pp: 480–699.

Carpenter, R. L., and Lo, H., 2014. STAT3 Target Genes Relevant to Human Cancers. *Cancers*, 6, pp. 897–925.

CCRC, 2009. Prosedur Tetap Cancer Chemoprevention Research Center Fakultas Farmasi UGM.

Cell Signaling Technology, 2017. A Guide to Successful Immunofluorescence. Available online : http://media.cellsignal.com/www/pdfs/resources/product-literature/application-if-brochure.pdf (diakses: 19 Agustus 2020).

Chen., P.P., Li, C.Y., Han, Y., Chen, X.Y., Liu, H.L., Du, Y.M., Su, S.W., Z, Y.J., 2015. N-[4-(4,6-Dimethyl-2-pyrimidinyloxy)-3-methylphenyl]-N'- [2-(dimethylamino)] benzoylurea induces cell-cycle arrest and apoptosis in human cancer cells. *Anti-Cancer Drugs*, 26(6), pp. 620-631.

Chen, J., Zeng, F., Forrester, S.J., Eguchi, S., Zhang, M.Z., Harris, R.C., 2016. Expression and function of the epidermal growth factor receptor in physiology and disease. *Physiological Reviews*, 96, pp. 1025-1069.

Chu, B., Liu, F., Li, L., Ding, C., Chen, K., Sun, Q., Shen, Z., Tan, C., Jiang, Y., 2015. A benzimidazole derivative exhiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. *Cell Death and Disease*, 6, e1686. pp.1-10.

Chung, S.S., Giehl, N., Wu, Y., Vadgama, J.V., 2014. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. *International Journal of Oncology*, 44, pp. 403-411

Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J. and Shi, B., 2015. Breast cancer intrinsic subtype classification. clinical use and future trends. *American Journal of Cancer Research*, 5(10), pp. 2929–2943.

Dinaryanti, A., Karsari, D., Ertanti, N., Ihsan, I., Ariyanti, A., Rantam, F.A., Aulanni'am, A., Purwati, 2019. Isolation and characterization of skin derived mesenchymal stem cell (SMSCs) from New Zealand rabbit, *oryctolagus* cPuniculus: a in vitro study. *Biochemical and Cellular Archives*, 19(2), pp. 4797-4801.

Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., Posey, L. M., 2016. *Pharmacotherapy: A Pathophysiologic Approach*. 10th ed. New York: McGraw-Hill.

Dittmann, K., Mayer, C., Czemmel, S., Huber, S.M., Rodemann, H.P., 2017. New roles for nuclear EGFR in regulating the stability and translation of mRNAs associated with VEGF-signaling. *Plos One*, 12(12), e0189087, pp. 1-21.

Diyah, N.W., Siswandono, Hardjono, S., Purwanto, B.T., 2013. Pemodelan Molekul dan Hubungan Kuantitatif Struktur-Aktivitas Sitotoksik Turunan Benzoilurea Sebagai Antitumor. *Berkala Ilmiah Kimia Farmasi*, 2(2), hal. 20-27.

Diyah, N.W., Ekowati, J., Siswandono, 2014. Synthesis And Antitumor Activity Evaluation of *N,N'-dibenzoyl-N,N'-diethylurea* Against Human Breast Cancer Cell Line (MCF-7). *International Journal of Pharmacy and Pharmaceutical Sciences*. 6(2), pp. 315-318.

Diyah, N.W., Purwanto, B.T., Siswandono, 2015. Synthesis, molecular docking and antitumor activity of N,N'-carbonylbis(N-ethylbenzamide). *World Journal of Pharmaceutical Sciences*. 3(7), pp. 1324-1329.

ECACC-European Collection of Authenticated Cell Cultures, 2016. Cell line profile: Vero (catalogue no. 84113001).

Eckert, L.B., Repasky, G.A., Ulku, A.S., McFall, A., Zhou, H., Sartor, C.I., Der, C.J., 2004. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. *Cancer Research*, 64, pp. 4585-4592.

Elkablawy, M.A., Albasri, A.M., Mohammed, R.A., Hussainy, A.S., Nouh, M.M., Alhujaily, A.S., 2016. Ki67 expression in breast cancer. *Saudi Medical Journal*, 37(2), pp. 137-141.

Eustace, A.J., Conlon, N.T., McDermott, M.S.J., Browne, B.C., O'Leary, P., Holmes FA, et al., 2018. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. *BMC Cancer*, 18, 965.

Farida, A., Wresnindyatsih, Yuliantini, V., 2019. Correlation CD24 and CD44 expression against aggressiveness breast cancer. In: IOP Conference Series, *Journal of Physics: Conf. Series* 1246 012012, pp. 1-6.

Faridi, N., Bathaie, S.Z., Abroun, S., Farzaneh, P., Karbasian, H., Tamanoi, F., Mohagheghi, M.A., 2018. Isolation and characterization of the primary epithelialbreast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. *Cytotechnology*, 70, pp. 625–639.

Ferreira, P.M.P., and Pessoa, C., 2017. Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges. *Brazilian Journal of Pharmaceutical Sciences*, 53(2), e16076, pp.1-17.

Galie, M., 2019. RAS as supporting actor in breast cancer. *Frontiers in Oncology*, 9(1199), pp. 1-9.

GLOBOCAN, The Global Cancer Observatory, 2018. Available online: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf (diakses: 6 December 2019).

Handala, L., Fiore, T., Rouille, Y., Helle, F., 2019. QuantIF: an imageJ macro to automatically determine the percentage of infected cells after immunofluorescence. *Viruses*, 11(165), pp. 1-4.

Hashmi, A.A., Hashmi, K.A., Irfan, M., Khan, S.M., Edhi, M.M., Ali, J.P., Hashmi, S.K., Asif, H., Faridi, N., Khan, A., 2019**.** Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. *BMC Research Notes*, 12(605), pp. 1-5.

Hassan, M., Watari, H., AbuAlmaaty, A., Ohba, Y., Sakuragi, N., 2014. Apoptosis and molecular targeting therapy in cancer. *BioMed Research International*, 2014, pp. 1-23.

Hawthorne, V.S., Huang, W.C., Neal, C.L., Tseng, L.M., Hung, M.C., Yu, D., 2009. ErbB2-mediated Src and STAT3 Activation Leads to Transcriptional Upregulation of $p21^{Cip1}$ and Chemoresistance in Breast Cancer Cells. *Molecular Cancer Research*, 7(4), pp. 592-600

Hincliffe, 2008. *Molecular Modelling for Begginners*. 2nd ed. Chichester: John Wiley and Sons Ltd.

Huang, M., Li, Y., Zhang, H., Nan, F., 2010. Breast cancer stromal fibroblasts promote the generation of $CD44^{+}CD24^{-}$ cells through SDF-1/CXCR4 interaction. *Journal of Experimental & Clinical Cancer Research*, 29(80), pp. 1-10.

Igbal, N., and Igbal, N., 2014**.** Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. *Molecular Biology International*, 2014, pp. 1-9.

International Agency for Research on Cancer, World Health Organization. Available online: https://www.who.int/cancer/PRGlobocanFinal.pdf, (diakses: 18 November 2019).

Jaggupilli,A., and Elkord, E., 2012. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. *Clinical and Developmental Immunology*, 2012, pp. 1-11.

Jaswir, I., Noviendri, D., Salleh, H.M., Taher, M., Miyashita, K., 2011. Isolation of fucoxanthin and fatty acids analysis of *Padina australis* and cytotoxic effect of fucoxanthin on human lung cancer (H1299) cell lines. *African Journal of Biotechnology*, 10(81) pp. 18855-18862.

Jensen, F., 2007. *Introduction to Computational Chemistry*, 2nd Ed, Chichester: John Wiley & Sons Ltd.

Jensen, E.C., 2013. Quantitative analysis of histological staining and fluorescence using imageJ. *The Anatomical Record*, 296, pp. 378-381.

Jing, X., Cui, X., Liang, H., Hao, C., Yang, Z., Li, X., Yang, X., Han, C., 2018. CD24 is a potential biomarker for prognosis in human breast carcinoma. *Cellular Physiology and Biochemistry*, 48, pp. 111-119.

Juergens, R. A., Bratman, S. V, Tsao, M., Laurie, S. A., Kuruvilla, S., Razak, A. R. A. and Hansen, A. R., 2017. Biology and Patterns of Response to EGFR-Inhibition in Squamous Cell Cancers of the Lung and Head & Neck. *Cancer Treatment Reviews*, 2017, pp.1-41.

Katz, M., Amit., I., Yarden, Y., 2007. Regulation of MAPKs by growth factors and receptor tyrosine kinases. *Biochimica et Biophysica Acta*, 1773, pp. 1161-1176.

Kransinskas, A.M., 2011. EGFR signaling in colorectal carcinoma. *Pathology Research International*, volume 2011, pp.1-6.

Kresno, S. B., 2011. Ilmu Dasar Onkologi. Edisi ke-2. Jakarta: Fakultas Kedokteran Universitas Indonesia, hal. 1, 12-16, 70-75.

Kristiansen, G., Winzer, K.J., Mayordomo, E., Bellach, J., Schluns, K., Denkert, C., Dahl, E., Pilarsky, C., Altevogt, P., Guski, H., Dietel, M., 2003. CD24 expression is a new prognostic marker in breast cancer. *Clinical Cancer Research*, 9, pp. 4906-4913.

Leslie, K., Lang, C., Devgan, G., Azare, J., Berishaj, M., Gerald, W., Kim, Y. B., Paz, K., Darnell, J. E., Albanese, C., Sakamaki, T., Pestell, R. and Bromberg, J., 2006. Cyclin D1 Is Transcriptionally Regulated by and Required for Transformation by Activated Signal Transducer and Activator of Transcription 3. *Cancer Research*, 66(5), pp. 2544–2553.

Li, H.Q., Yan, T., Yang, Y., Shi, L., Zhou, C.F., Zhu, H.L., 2010. Synthesis and structure-activity relationships of *N*-benzyl-*N*-(X-2-hydroxybenzyl)-*N*'-phenylureas and thioureas as antitumor agents. *Bioorganic & Medicinal Chemistry*, 18, pp. 305-313.

Li, L., Zhao, G.D., Shi, Z., Qi, L.L., Zhou, L.Y., Fu, Z.X., 2016. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC (Review). *Oncology Letters*, 12, pp. 3045-3050.

Li, W., Ma, H., Zhang, J., Zhu, L., Wang, C., Yang, Y., 2017. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. *Scientific Reports*, 7(13856), pp. 1-15.

Lin, X. Y., He, C. D., Xiao, T., Jin, X., Chen, J., Wang, Y. K., Chen, H. D., 2009. Acitretin induces apoptosis through CD95 signalling pathway in human cutaneous squamous cell carcinoma cell line SCL-1. *Journal of cellular and molecular medicine*, 13(9a), pp. 2888-2898.

Liu, J., and Wang, Z., 2015. Increased Oxidative Stress as a Selective Anticancer Therapy. *Oxidative Medicine and Cellular Longevity*, volume 2015, pp. 1-12.

Lobba, A.R.M., Forni, M.F., Carreira, A.C.O., Sogayar, M,C., 2012. Differential Expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. *Cytometry*, 81A, pp. 1084-1091.

Ma'at, S., 2011. *Teknik Dasar Kultur Sel*. Surabaya: Airlangga University Press, hal. 3-19, 27, 55-61, 64-65.

Ma, J.H., Qin, L., Li, X., 2020. Role of STAT3 signaling pathway in breast cancer. *Cell Communication and Signaling*, 18(33), pp. 1-13.

Madaan, K., Kaushik, D., Verma, T., 2012. Hydroxyurea: a key player in cancer chemotherapy. *Journal Expert Review of Anticancer Therapy*, 12(1), pp. 19-29.

McMurry, J.M., 2011. *Fundamental of Organic Chemistry*. 7th Ed. France: Brooks/Cole, pp. 349.

Mulyani, N. S., dan Nuryani, 2013. *Kanker payudara dan PMS pada kehamilan*. Yogyakarta: Nuha Medika.

Nami B, Maadi H, Wang Z., 2018. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. *Cancers*, 10 (342), pp. 1-21.

Nikhil, K., Sharan, S., Chakraborty, A., Bodipati, N., Peddinti, R.K., Roy, P., 2014. Role of isothiocyanate conjugate of pterostilbene on the inhibition of MCF-7 cell proliferation and tumor growth in Ehrlich ascitic cell induced tumor bearing mice. *Experimental Cell Research*, 320, pp. 311-328.

Nushtaeva, A.A., Stepanov, G.A., Semenov, D.V., Juravlev, E.S., Balahonova, E.A., Gerasimov, A.V., Sidorov, S, V., Savelyev, E.I., Kuligina, E.V., Richter, V.A., Koval, O.A., 2018. Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents. *BMC Cancer*, 18(728), pp. 1-11.

Panieri, E., and Santoro, MM., 2016. ROS homeostasis and metabolism : a dangerous liason in cancer cells. *Cell Death and Disease*, 7, pp. 1-12.

Pavia, D.L, Lampman, G.M., Kriz, G.S., James, R., Vyvyan, J.R., 2015. *Introduction of Spectroscopy*. 5th Ed. Boston: Cengage Learning.

Phuc, P.V., Khuong, T.T.T., Dong, L.V., Kiet, T.D., Giang, T.T., Ngoc, P.K., 2010. Isolation and characterization of breast cancer stem cells from malignant tumours in vietnamese women. *Journal of Cell and Animal Biology*, 4(12), pp. 163-169.

Plavetic, N.D., Kulic, A., Vrbanec, D., 2012. Role of HER2 signaling pathway in breast cancer : biology, detection and therapeutical implications. *Periodicum Biologorum*, 114(4), pp. 505-510.

Prabha, A. G. T., and Sekar, D., 2017. Deciphering the molecular signaling pathways in breast cancer pathogenesis and their role in diagnostic and treatment modalities. *Gene Reports*, doi: http://dx.doi.org/10.1016/j.genrep.2017.01.003.

Prenzel, N., Fisher., O.M., Streit, S., Ullrich, H., 2001. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. *Endocrine-Related Cancer*, 8, pp. 11-31.

Qian, Q., Chen, W., Cao, Y., Cao, Q., Cui, Y., Li, Y., Wu, J., 2019. Targeting reactive oxygen species in cancer via chinese herbal medicine. *Oxidative Medicine and Cellular Longevity*, 2019, pp. 1-23.

Ragab, H.M., Samy, N., Afify, M., Maksoud, N.A.E., Shaaban, H.M., 2018. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. *Journal of Genetic Engineering and Biotechnology*, 16, pp. 479-484.

Rai, Y., Pathak, R., Kumari, N., Sah, D.K., Pandey, S., Kalra, N., Soni, R., Dwarakanath, B.S., BHATT, A.N., 2018. Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. *Scientific Reports*, 8(1531), pp. 1-15.

Rang, H. P., Dale M. M., & Ritter J. M., 2016. *Pharmocology*. 8th Ed, Churchill Livingstone, USA.

Rashidi, M., Seghatoleslam, A., Namavari, M., Amiri, A., Fahmidehkar, M.A., Ramezani, A., Eftekhar, E., Hosseini, A., Erfani, N., Fakher, S., 2017. Selective cytotoxicity and apoptosis-induction of Cyrtopodion scabrum extract against digestive cancer cell lines. *International Journal of Cancer Management*, 10(5):e8633, pp. 1-7.

Riesco, A., Santos-Buitrago, B., Rivas, J.D.L., Knapp, M., Santos-Garcia, G., Talcott, C., 2017. Epidermal Growth Factor Signaling towards Proliferation: Modeling and Logic Inference Using Forward and Backward Search. *Biomed Research International*, 2017, pp. 1-11.

Scaltriti, M., and Baselga, J., 2006. The epidermal growth factor receptor pathway: a model for targeted therapy. *Clinical Cancer Research*, 12(18), pp. 5268-5272.

Schroeder, R.L., Steven, C.L., Sridhar, J., 2014. Small Molecule Tyrosine Kinase Inhibitor of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer. *Molecules*, 19, pp. 15196-15212.

Segovia-Mendoza, M., Gonzalez-Gonzalez, M.E., Barrera, D., Diaz, L., Garcia-Becerra, R., 2015. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. *American Journal of Cancer Research*, 5(9), pp. 2531-2561.

Shah, D., and Osipo, C., 2016. Cancer stem cells and HER2 positive breast cancer: The story so far. *Genes & Diseases*, 3 (2016), pp. 114-123.

Simanshu, D. K., Nissley, D. V and McCormick, F., 2017. RAS Proteins and Their Regulators in Human Disease. *Cell*, 170(1), pp. 17–33.

Simper, N. B., Jones, C. L., Maclennan, G. T., Montironi, R., Williamson, S. R., Osunkoya, A. O., Wang, M., Zhang, S., Grignon, D. J., Eble, J. N., Tran, T., Wang, L., Ann, L., Ba, B., Ajcp, H. T., and Cheng, L., 2015. Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression and overexpression of EGFR. *Human Pathology*, 2015, pp. 1-8.

Singh, M., and Jadhav, H. R., 2017. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. *Drug Discovery Today*, 2017, pp.1-12.

Silverstein, R. M., Webster F. X., Kiemle D. J., 2015, *Spectometric Identification of Organic Compounds*. 8th Ed, John Wiley and Sons. Inc.

Siswandono, 2016. *Kimia Medisinal*. Edisi ke-2. Surabaya: Airlangga University Press.

Siswandono, 2003. The Synthesis of Benzoylurea and the Activity Test of Central Nervous System Depresssant in Mus Musculus. *Jurnal Biosains Pascasarjana*, 5(1), pp. 10–16.

Sirkisoon, S.R., Carpenter, R.L., Rimkus, T., Miller, L., Barlow, L.M., Lo, H.W., 2016. EGFR and HER2 signaling in breast cancer brain metastasis. *Frontiers in Bioscience (Elite Ed),* 8, pp. 245-263.

Smith, S.M., and Cai, L., 2012. Cell specific CD44 expression in breast cancer requires the interaction of AP-1 and NFkB with a Novel *cis*-element. *Plos One*, 7(11), e50867, pp. 1- 12.

Sogabe, S., Kawakita, Y., Igaki, S., Iwata, H., Miki, H., Cary, D.R., Takagi, T., Takagi, S., Ohta, Y., Ishikawa, T., 2012. Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. *ACS Medicinal Chemistry Letters*, 2013(4), pp. 201-2015.

Sonnenblick, A.,Brohee, S., Fumagalli, D., Vincent, D., Venet, D., Ignatiadis, M., Salgado, R., Eynden, G.V.D., Rothe, F., Desmedt, C., et al., 2015. Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. *BMC Medicine*, 13 (177), pp. 1-10.

Sudiana, I. K., 2011. *Patobiologi Molekuler Kanker*. Jakarta: Salemba Medika.

Suhud, F., Siswandono, Budiati, T., 2015. Synthesis and activity evaluation of a novel lead compound *1-benzyl-3-benzoylurea* as antiproliferative agent. *World Journal of Pharmaceutical Sciences*, 3(2), pp. 192-195.

Tobias, J. and Hochhauser, D., 2010. *Cancer and its management*. 10th ed. Oxford: John Wiley and Sons Ltd.

Tsang, R.Y., Sadeghi, S., Finn, R.S., 2011. Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside. *Clinical Medicine Insights: Therapeutics*, 3, pp. 1-13.

Verhoeven, Y., Tilborghs, S., Jacobs, J., Waele, J.D., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X.B., Wouters, A., Smits, E.L.J., Lardon, F., Dam, P.A.V., 2020. The potential and controversy of targeting STAT family members in cancer. *Seminars in Cancer Biology*, 60, pp. 41-56

Wang, J., and Yi, J., 2008. Cancer cell killing via ROS. *Cancer Biology & Therapy*, 7(12), pp. 1875-1884.

Watson, D.G., 2010. *Pharmaceutical Analysis: A Textbook of Pharmacy Student and Pharmaceutical Chemists*. 3rd Ed, London: Churchill Livingstone.

Wee, P., and Wang, Z., 2017. Epidermal growth factor receptor cell proliferation signaling pathways. *Cancers*, 9(52), pp. 1-45.

Whalen, K., Finkel, R., Panavelll, T. A., 2015. *Illustrated Reviews: Pharmacology*. 6th ed. Philadelphia: Wolters Kluwer.

Wu, D., and Yotnda, P., 2011. Production and detection of reactive oxygen species (ROS) in cancers. *Journal of Visualized Experiments*, 57, e3357, pp. 1-4.

Yallowitz, A., Garcia, L., Alexandrova, E.M., Marchenkon, N., 2018. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells. *Cell Death and Disease*, 9, 621.

Yamaguchi, H., Chang, S-S., Hsu, J.L., Hung, M-C., 2014. Signaling cross-talk in the resistance to HER family receptor targeted therapy. *Oncogene*, 33, pp. 1073-1081.

Yamashita, N., Kondo, M., Zhao, S., Li, W., Koike, K., and Nemoto, K., 2017. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR / STAT3 signaling pathway. *Bioorganic & Medicinal Chemistry Letters*, 231, pp. 3–7.

Zulkifli, A. A., Tan, F. H., Putoczki, T. L., Stylli, S. S., and Luwor, R. B., 2017. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. *Molecular and Cellular Endocrinology*, 451, pp 15-23.